Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -588,181 | -513,512 | -419,696 | -198,704 | -742,745 |
| Depreciation Amortization | 62,343 | 46,596 | 30,428 | 16,363 | 63,257 |
| Income taxes - deferred | 3,283 | 7,793 | 6,346 | 0 | 281 |
| Accounts receivable | -110,098 | -88,735 | -21,197 | -5,863 | 7,428 |
| Accounts payable and accrued liabilities | -1,709 | 6,283 | -3,033 | -23,556 | 25,048 |
| Other Working Capital | -85,950 | -118,955 | -76,270 | -97,908 | -70,976 |
| Other Operating Activity | 354,880 | 265,955 | 150,920 | 87,432 | 144,595 |
| Operating Cash Flow | $-365,432 | $-394,575 | $-332,502 | $-222,236 | $-573,112 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -45,302 | -32,775 | -23,978 | -10,558 | -51,201 |
| Net Acquisitions | -80,000 | -80,000 | -80,000 | N/A | -10,000 |
| Purchase Of Investment | -633,041 | -292,135 | -125,655 | -125,655 | -1,424,172 |
| Sale Of Investment | 1,067,443 | 804,588 | 741,725 | 371,423 | 1,557,938 |
| Other Investing Activity | -40,244 | -8,132 | -19,611 | -21,172 | 9,444 |
| Investing Cash Flow | $268,856 | $391,546 | $492,481 | $214,038 | $82,009 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 23,662 | 13,386 | N/A | 13,386 | 294,243 |
| Debt Repayment | -19,954 | -16,515 | -1,055 | -4,497 | -21,443 |
| Common Stock Issued | 185,592 | 139,689 | 87,850 | 41,616 | 274,615 |
| Other Financing Activity | -381 | -281 | -184 | -91 | 1,824 |
| Financing Cash Flow | $188,919 | $136,279 | $86,611 | $50,414 | $549,239 |
| Exchange Rate Effect | -2,834 | -2,259 | -1,306 | -2,596 | -2,176 |
| Beginning Cash Position | 625,259 | 625,259 | 625,259 | 625,259 | 569,299 |
| End Cash Position | 714,768 | 756,250 | 870,543 | 664,879 | 625,259 |
| Net Cash Flow | $89,509 | $130,991 | $245,284 | $39,620 | $55,960 |
| Free Cash Flow | |||||
| Operating Cash Flow | -365,432 | -394,575 | -332,502 | -222,236 | -573,112 |
| Capital Expenditure | -45,302 | -32,775 | -23,978 | -10,558 | -51,201 |
| Free Cash Flow | -410,734 | -427,350 | -356,480 | -232,794 | -624,313 |